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Slowing the progression of renal failure. In recent years several enzyme inhibitors (ACEI) or with angiotensin II subtype
multicentric prospective studies have demonstrated the efficacy 1 receptor antagonists (ARA) slow the progression of
of some therapeutic measures to slow the progression of renal renal failure in many chronic nephropathies. Severaldiseases. Inhibition of renin-angiotensin system (RAS) both
large, multicentric, and prospective studies have shownby ACE inhibitors (ACEI) and angiotensin II receptor antago-
a significant reduction in the risk of doubling baselinenists (ARA) is probably the strongest therapeutic alternative:
The antiproteinuric effect of these drugs is an excellent surro- serum creatinine or progression toward end-stage renal
gate marker and a predictor of the beneficial influences on failure in patients with type 1 and type 2 diabetic ne-
the progression of renal failure. The type of renal disease,
phropathy treated with ACEI or ARA, in comparisonan inadequate control of blood pressure, and the presence
with control patients [1–4]. Similarly, these drugs haveof obesity may counteract the beneficial influences of RAS
inhibition, whereas early treatment of all patients with signifi- shown a clear renoprotective effect in proteinuric non-
cant proteinuria before the appearance of renal insufficiency diabetic chronic nephropathies [5, 6]. The accumulating
and combined therapy with an ACEI and an ARA may aug- evidence of the beneficial effects offered by ACEI andment it. Dietary protein restriction is a classic treatment of
AT1RA has led to the generalized use of these drugschronic renal insufficiency whose effectiveness has been vali-
dated by multicentric studies. However, a poor compliance of in both diabetic and non-diabetic nephropathies. Some
the patient and the risk of malnutrition with very strict protein patients may exhibit a clear beneficial response, with
restriction could limit the benefits of this treatment. Treatment dramatic proteinuria decrease and stabilization of GFRof hyperlipidemia, prevention of obesity, avoidance of smok-
over the years. However, a review of the referred multi-ing, and regular physical exercise are interventions whose ther-
centric trials [1–6] shows that the number of patients thatapeutic potential is progressively recognized, particularly in
type 2 diabetic nephropathy. Early correction of anemia may reach the most commonly analyzed primary outcome
contribute to the slowing of renal disease progression. Al- (doubling of baseline SCr) is still considerably high. Thus,though further studies are required, the accumulated evidence
in the AIPRI and REIN studies, which included prefera-and the likelihood of additive beneficial effect of these thera-
bly non-diabetic nephropathies, 10–30% of the patientspeutic measures advise their combined implementation in pa-
tients with chronic renal diseases. treated with ACEI had doubled the baseline serum creat-
inine (SCr) after 2–3 years of follow up [5, 6]. In the studies
performed with diabetic patients [1–4], the number of
A large number of experimental studies have demon- patients doubling baseline SCr reached 20–40% among
strated that renal diseases share pathogenic mechanisms those treated with ACEI and ARA, after 2.5–3.5 years
that play a fundamental role in the progression toward of follow up. Although the number of patients reaching
end-stage renal failure, independently of the original primary outcomes was significantly higher in control
etiology. In recent years a number of therapeutic mea- groups, these results indicate that RAS inhibition with
sures that can halt or slow these common, harmful patho- ACEI or ARA should not be considered, unfortunately,
genic ways have emerged. In this article, we review some
as the definitive defeat of renal failure progression.of the most relevant new insights in the field of general
renoprotective measures.
PROTEINURIA AS A SURROGATE MARKER
OF THE EFFECTIVENESS OF RAS INHIBITIONINHIBITION OF THE RENIN-ANGIOTENSIN
SYSTEM (RAS) The antiproteinuric effect of ACEI is well known after
numerous studies performed in the past 15 years [7].There is compelling clinical evidence that the pharma-
cologic inhibition of RAS with angiotensin-converting More recently, ARA have demonstrated a similar effect.
A review of the mechanisms implicated in this beneficial
effect, shared so far by all classes of ACEI and ARAKey words: ACE inhibitors, proteinuria, angiotensin II receptor antag-
onists, obesity, hyperlipidemia. so far, is beyond the scope of this article. In 1992 we
reported, for the first time, that in those captopril-treated 2002 by the International Society of Nephrology
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patients showing a substantial proteinuria decrease, a phropathy, significant reductions of functioning renal
mass whatever the cause, healed crescentic glomerulone-clear slowing in the progression of renal insufficiency
was observed. On the contrary, those patients also phritis) show a striking proteinuria decrease after the
introduction of an ACEI, with reductions of 55–65% oftreated with captopril but in whom no significant protein-
uria decrease was observed, continued to show a progres- the baseline values [8]. In the same study, we observed
an also satisfactory response among patients with IgAsive loss of renal function [8]. Interestingly, the protein-
uria decrease was unrelated to blood pressure changes nephropathy (43%) and benign nephroangiosclerosis
(58%). On the contrary, patients with idiopathic focalin our study, and several studies have confirmed our
results later. Very importantly, in all the above-cited and segmental glomerulosclerosis (FSG) and membra-
nous glomerulonephritis showed a less evident response,multicentric landmark studies [1–6], the slowing in the
progression of renal insufficiency has always strongly with proteinuria decreases oscillating between 24% and
27% [8]. However, it is important to remark that a strik-been related to proteinuria decrease induced by ACEI
or ARA, whereas it appears to be largely independent ing variability in the response was also observed within
each specific diagnosis group. Thus, some patients withof the blood-pressure lowering effects induced by these
drugs. Because the proteinuria decrease is already ob- membranous GN or idiopathic FSG showed proteinuria
decreases higher than 50%.served within the fist weeks or months of treatment, it
should be considered as an excellent clinical predictor of
Adequate blood pressure controlthe long-term renoprotective effects of RAS inhibition.
Therefore, there is mounting evidence that the level of Given the results obtained in the Modification of Diet
in Renal Disease Study (MDRD), blood pressure controlproteinuria is of paramount importance in order to moni-
tor the effectiveness of ACEI and/or ARA in proteinuric should be targeted to values 130/80 mm Hg in patients
with proteinuric nephropathies [9]. The basis of antihy-nephropathies. Some authors have suggested that the
pertensive therapy should be the inhibition of RAS sys-definitions of partial or complete remissions (proteinuria
tem, either with an ACEI or an ARA, because of theirdecreases to 2.5 g/24 h and 0.5 g/24 h, respectively),
demonstrated renoprotective and antiproteinuric effects.commonly used to define the responses to immunosup-
However, if the recommended target is not reached afterpressive drugs in many glomerular diseases, should also
an appropriate and progressive increase of doses, otherbe applied to evaluate the response of chronic protein-
antihypertensive drugs should be added, according touric nephropathies when ACEI/ARA are introduced.
the individual patient’s characteristics.On the other hand, the absence of a significant antipro-
teinuric response should be considered as a resistance
Genetic basisto the beneficial effects of these drugs. In this case, an
Efforts to characterize genetic peculiarities that cananalysis of those factors that may contribute to the resis-
contribute to a better or poorer response to the renopro-tance should be performed.
tection offered by ACEI and ARA have been mainly
concentrated on polymorphisms of genes coding the con-
FACTORS THAT CONTRIBUTE TO stituents of RAS. Some studies have reported a greater
THE FAILURE OF ACEI/ARA antiproteinuric effect of ACEI in patients with the II
ANTIPROTEINURIC EFFECT genotype of the ACE [10]. On the contrary, a greater
A significant number of patients treated with ACEI/ renoprotective efficacy of these drugs in patients with
ARA did not show a clear antiproteinuric response, and the DD genotype has been found in non-diabetic ne-
this failure heralds a progressive loss of renal function phropathies [11]. These contradictory results should be
in most cases [1–8]. The factors that may contribute to resolved with more extensive studies and the analysis of
this resistance are largely unknown, but their identifica- other RAS genes.
tion and correction should have an obvious clinical im-
Obesityportance to slow the progression of renal insufficiency
more effectively in proteinuric renal diseases. Some clini- We have described that both weight loss and ACEI
cal studies have brought forward interesting data in this can induce a dramatic proteinuria decrease in patients
field. with obesity related proteinuria [12]. However, when we
analyzed the long-term evolution of patients with FSG
Clinical diagnosis associated with obesity, we found that most patients es-
Although the number of clinical studies concerning caped from the antiproteinuric effect of ACEI after the
this issue is relatively scarce, the antiproteinuric response 6–12 months of treatment [13]. In many cases, this later
to RAS inhibition appears to be influenced by the type failure of the ACEI-induced proteinuria decrease was
of renal disease. Thus, we have reported that those renal correlated to further weight gains that many patients
exhibited. These findings are of interest, taking into ac-diseases defined as “hyperfiltration disorders” (reflux ne-
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count that, in our experience, the long-term prognosis Combined treatment with ACEI and ARA
of obesity associated FSG is poorer than previously con- From a theoretical point of view, the combined use
sidered, with almost 50% of patients developing end- of an ACEI and an ARA would augment the beneficial
stage renal failure [13]. In addition, the prevalence of influences of both classes of agents: ARA would provide
obesity related glomerulopathies has dramatically in- a complete blocking of AT1 receptors of angiotensin II,
creased in the past years, as has been pointed out recently not guaranteed by ACEI, whereas the later would contrib-
[14], and a great majority of type 2 diabetics are obese. ute with an increased synthesis of bradykinin. In clinical
We have observed obese patients with different ne- practice, a greater antiproteinuric effect of the combina-
tion ACEIARA in comparison with single therapy withphropathies and resistance to the antiproteinuric effect
an ACEI or an ARA has been reported in patients withof ACEI or ARA that showed a marked proteinuria
IgAnephropathy [16]. In the last two meetings of the ASN,reduction coinciding with weight loss. All these data
more than 20 studies have analyzed the antiproteinuricsuggest that obesity could be considered a condition of
effect of the combination ACEIARA, and nearly allincreased resistance to the beneficial renal effects of
have found it significantly greater than the one observedRAS inhibition.
with just ACEI or ARA, although the doses of these
drugs were increased when used alone. Interestingly,
FACTORS THAT CAN IMPROVE THE no differences in blood pressure that could explain the
EFFECTIVENESS OF RAS INHIBITION greater antiproteinuric effect of the combination were
observed. Although other published studies have notEarly treatment
confirmed the superiority of the combination [17], pro-ACEI and ARA have confirmed their efficacy to slow
spective multicentric studies including a larger number
the progression of renal failure in several multicentric
of patients should be performed in order to evaluate
and prospective studies [1–6]. The majority of patients definitely the indication of the ACEIARA combina-
included in these studies had different degrees of chronic tion in proteinuric diseases.
renal insufficiency. Nevertheless, some data strongly in-
dicate that the introduction of RAS inhibitors in chronic
PROTEIN RESTRICTIONproteinuric nephropathies before the appearance of re-
nal insufficiency should be the preferable option. Thus, An in-depth review of the beneficial effects of low
studies in type 1 and type 2 diabetes mellitus have dem- protein diets on the progression of renal failure is beyond
onstrated that treatment with ACEI or ARA in patients the scope of this article, but several meta-analyses and
with microalbuminuria significantly decrease the risk of secondary analyses of randomized trials have demon-
strated that protein restriction slows the progression ofdeveloping overt diabetic nephropathy [4, 15]. At pres-
renal diseases [18, 19]. Protein intakes of 0.6–0.7 g/kg/ent, data about early treatment of non-diabetic protein-
day are the most commonly recommended in patientsuric nephropathies are scarce. Since 1987 we have fol-
with GFR50–55 mL/min/1.73 m2. In addition, low pro-lowed a prospective therapeutic protocol with ACEI or
tein diets induce a significant proteinuria decrease, i.e.,ARA in patients with IgA nephropathy and proteinuria
additive to that achieved by ACEI [20]. However, some1 g/24 h, regardless of blood pressure and renal func-
potential limitations of low protein diets have beention status. We have analyzed recently the evolution of
pointed out by several studies. Thus, the patient’s com-those patients that started treatment when SCr was 1.5
pliance has been rather low in some studies; a risk ofmg/dL: After 5 years of follow up renal survival (defined
malnutrition should be considered, particularly whenas the absence of a SCr increase higher than 50% of
very strict protein restriction is prescribed to patientsbaseline values) was 100% (Kaplan-Meier analysis). By
with advanced renal failure; and the benefits obtainedcontrast, renal survival at 5 years was only 65% in pa-
by protein restriction, although evident, are rather mod-tients with the same characteristics that were not treated
est in terms of the delay in the start of chronic dialysiswith ACEI or ARA (abstract; Gonza´lez et al, J Am
that we obtain with this dietary intervention [21].Soc Nephrol 12:102A, 2001). In our experience, it is not
uncommon to observe similar satisfactory responses to
TREATMENT OF HYPERLIPIDEMIARAS inhibition in other nephropathies when the treat-
ment is started early in the course of the disease. We The pathogenic role of hyperlipidemia has been dem-
believe that ACEI or ARA should be administered to all onstrated in several experimental models of progressive
patients with chronic renal diseases showing significant renal diseases: Mesangial cells posses receptors for LDL-
proteinuria values (0.5–1 g/24 h) regardless of blood cholesterol, and LDL-cholesterol stimulates the prolifer-
pressure and preferably before the appearance of renal ation of mesangial cells and their extracellular matrix.
Conversely, treatment of hyperlipidemia with clofibratesinsufficiency.
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or statins induces a clear improvement of renal lesions in The influence of obesity on the progression of renal
diseases could be related to the emerging hypothesis thatthese experimental models. In spite of the accumulating
experimental evidence, clinical trials aimed at demon- emphasizes the importance of intrauterine/congenital
factors in the predisposition to suffer some diseases instrating the role of hyperlipidemia in human renal dis-
eases have been disappointing so far because, with some adulthood. Experimental studies have demonstrated that
an inadequate protein intake in pregnant experimentalexceptions, no differences in the level of proteinuria or
in the progression of renal failure were found between animals leads to the birth of animals with a reduced
number of nephrons and endocrine pancreatic tissuepatients treated with lipid-lowering drugs and controls.
However, a very interesting meta-analysis of the previ- [24, 25]. Some autopsy studies performed in dead neo-
ous trial has been recently published [22]. Increasing the nates support the validity of these findings for the human
statistical power by the sum of these studies, a significant being, because the number of glomeruli was significantly
beneficial effect of antilipemic agents could be demon- lower among neonates with a birth weight2500 g com-
strated, with proteinuria decrease and slowing of renal pared with neonates with normal birth weight [26]. Epi-
failure progression in comparison with non-treated pa- demiologic studies coming from Britain, US, China, and
tients. Taking into account the high prevalence of hyper- other countries have confirmed an inverse relationship
lipidemia and cardiovascular events among patients with between weight at birth and the risk to develop hyperten-
renal diseases and the demonstrated preventive effects sion, type 2 diabetes mellitus and renal insufficiency in
of antilipemic agents (particularly statins) on the appear- adulthood [27]. In addition, a disproportionate tendency
ance of new cardiovascular events, it may be unethical (as to the development of hypertension, type 2 diabetes, and
the authors of the meta-analysis stated) to design long- end-stage renal disease has been repeatedly reported in
term prospective clinical trials with a group of hyperlipid- social groups such as Native Americans or Australian
emic patients with renal diseases serving as controls with- aborigines [28]. The prevalence of prematurity and low
out lipid-lowering treatment. birth weight is high among these groups, as well as the
prevalence of obesity in adulthood. Therefore, it could
be hypothesized that the presence of a reduced numberOBESITY, SEDENTARY LIFESTYLE, AND
of nephrons and pancreatic islets, determined by intra-OTHER SOCIOECONOMIC FACTORS IN THE
uterine factors mainly related to maternal nutrition, facil-PROGRESSION OF RENAL DISEASES
itates the development of hypertension, type 2 diabetes
As commented above, obesity may counteract the ben- and renal insufficiency. The development of obesity and
eficial antiproteinuric effects of ACEI and ARA. In addi- a sedentary lifestyle in adulthood could be the crucial
tion, obesity plays a facilitating role in the progresion factors to precipitate the appearance of these diseases.
of some renal diseases, particularly those mediated by According to this hypothesis, an adequate maternal nu-
hyperfiltration [23]. Nevertheless, the possible influence trition during pregnancy, and regular physical exercise
of overweight on the general progression of renal dis- and avoidance of obesity in adulthood, should decrease
eases, independent of their origin, has been scarcely in- the risk of progressive renal failure in the general popula-
vestigated. We have recently performed a prospective tion.
randomized study in overweight patients (body mass in-
dex27 kg/m2) with proteinuric renal diseases of several
SMOKINGetiologies. One half of the cases had type 2 diabetic
nephropathy. We have found that a moderate weight Several recently published retrospective studies have
loss (4.1  3% of the baseline values) by hypocaloric stressed the role of smoking in the progression of both
normoproteic diet induced a significant proteinuria de- diabetic and non-diabetic nephropathies [29]. Direct
crease higher than 30% of baseline together with stable harmful effects of smoking on kidney vascular beds have
GFR. On the contrary, a tendency to body weight and been demonstrated by other studies. Therefore, avoid-
proteinuria increases together with significant GFR de- ance of smoking should be strongly recommended to all
crease was observed in control group patients, who main- patients with renal diseases.
tained their dietary habits (abstract; Morales et al, J Am
Soc Nephrol 12:231, 2001). These results indicate that
EARLY CORRECTION OF ANEMIAtreatment of obesity should be an important target in
chronic proteinuric nephropathies. Taking into account Although some experimental studies had suggested
that anemia correction could hasten the progression ofthe increasing prevalence of obesity in the general popu-
lation and the fact that a great majority of patients with renal failure, clinical studies have shown that erythropoi-
etin improves anemia in predialysis patients and doestype 2 diabetic nephropathy (the leading cause of end-
stage renal disease) are obese, further studies are re- not accelerate the rate of renal failure progression [30].
Furthermore, recent studies have suggested that earlyquired to confirm these results.
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inhibitors induced renoprotection in chronic proteinuric nephropa-correction of anemia may induce a beneficial influence
thies. Kidney Int 57:274–281, 2000
retarding the progression of renal failure [31]. Hypoxia 12. Praga M, Herna´ndez E, Andres A, et al: Effects of body-weight
loss and captopril treatment on proteinuria associated with obesity.stimulates the progression of renal interstitial fibrosis
Nephron 70:35–41, 1995[32], and erythropoietin could counteract these harmful
13. Praga M, Herna´ndez E, Morales E, et al: Clinical features and
pathways. Prospective studies are warranted in order long-term outcome of obesity-associated focal segmental glomeru-
losclerosis. Nephrol Dial Transplant 16:1790–1798, 2001to assess these important implications of erythropoietin
14. Kambham N, Markowitz G, Valeri M, et al: Obesity-related glom-therapy.
erulopathy: An emerging epidemic. Kidney Int 59:1498–1509, 2001
15. The ACE Inhibitors in Diabetic Nephropathy Trialist Group:
Should all patients with diabetes mellitus and microalbuminuria
CONCLUSION receive angiotensin converting enzyme inhibitors? Ann Intern Med
134:370–379, 2001Several therapeutic interventions, briefly reviewed in
16. Russo D, Pisani A, Balletta MM, et al: Additive antiproteinuric
this article, have demonstrated a beneficial effect slowing effect of converting enzyme inhibitor and losartan in normotensive
patients with IgA nephropathy. Am J Kidney Dis 33:851–856the progression of renal diseases, and they are likely to
17. Agarwal R: Add-on angiotensin receptor blockade with max-have additive beneficial influences. Therefore, as it has
imized ACE inhibition. Kidney Int 59:2282–2289, 2001
been recently proposed [33], a multiple-risk-factor inter- 18. Levey A, Greene T, Beck G, et al: Dietary protein restriction and
the progression of chronic renal disease: What have all the resultsvention including all these possibilities appears to be
of the MDRD study shown? J Am Soc Nephrol 10:2426–2439, 1999the most plausible approach in patients with chronic
19. Kasiske B, Lakatua J, Ma J, et al: A meta-analysis of the effects
nephropathies. of dietary protein restrictions on the rate of decline in renal func-
tion. Am J Kidney Dis 31:954–961, 1998
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